Paul W Armstrong Selected Research

Heparin (Liquaemin)

1/2007	Comparison of effectiveness of enoxaparin versus unfractionated heparin to reduce silent and clinically apparent acute myocardial infarction in patients presenting with non-ST-segment elevation acute coronary syndrome.
10/2006	Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS.
5/2006	Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data.
2/2006	Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial.
4/2005	Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction.
8/2004	Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3).
7/2004	Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
12/2003	Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation.
10/2003	Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab.
8/2003	ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paul W Armstrong Research Topics

Disease

152	Myocardial Infarction 05/2022 - 01/2002
113	Acute Coronary Syndrome 11/2020 - 01/2002
110	ST Elevation Myocardial Infarction 05/2022 - 01/2003
107	Heart Failure 11/2022 - 01/2002
57	Hemorrhage 01/2020 - 01/2002
45	Stroke (Strokes) 01/2020 - 09/2003
27	Infarction (Infarctions) 01/2021 - 09/2003
20	Ischemia 03/2017 - 02/2002
16	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 01/2002
16	Unstable Angina 01/2020 - 01/2002
15	Shock 05/2022 - 09/2003
12	Hypertension (High Blood Pressure) 01/2021 - 01/2002
11	Dyspnea (Shortness of Breath) 01/2018 - 02/2009
10	Type 2 Diabetes Mellitus (MODY) 01/2022 - 07/2015
10	Atrial Fibrillation 01/2021 - 08/2009
9	Inflammation (Inflammations) 05/2022 - 12/2004
9	Diabetes Mellitus 01/2021 - 11/2012
8	Thrombosis (Thrombus) 05/2022 - 05/2002
8	Coronary Disease (Coronary Heart Disease) 01/2019 - 05/2002
7	Chest Pain (Chest Pains) 01/2017 - 04/2003
6	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2020 - 12/2004
6	Body Weight (Weight, Body) 01/2018 - 04/2005
6	Cardiogenic Shock 08/2015 - 10/2005
6	Necrosis 07/2012 - 07/2003
5	Hypotension (Low Blood Pressure) 01/2022 - 11/2014
5	Coronary Artery Disease (Coronary Atherosclerosis) 01/2022 - 06/2002
5	Atherosclerotic Plaque (Atheroma) 01/2019 - 05/2002
5	Non-ST Elevated Myocardial Infarction 01/2018 - 05/2006
5	Myocardial Ischemia (Ischemic Heart Diseases) 01/2007 - 01/2002
4	Cardiomyopathies (Cardiomyopathy) 01/2022 - 02/2015
4	Renal Insufficiency (Renal Failure) 03/2016 - 03/2004
3	Anemia 11/2021 - 10/2004
3	Chronic Renal Insufficiency 01/2021 - 10/2016
3	Vascular Diseases (Vascular Disease) 11/2020 - 01/2016
3	Peripheral Arterial Disease 01/2020 - 10/2014
3	Transient Ischemic Attack 05/2017 - 02/2010
3	Acute Kidney Injury (Acute Renal Failure) 08/2016 - 10/2015

Drug/Important Bio-Agent (IBA)

45	Brain Natriuretic Peptide (Natrecor)FDA Link 06/2021 - 04/2006
41	pexelizumabIBA 11/2020 - 09/2003
37	Biomarkers (Surrogate Marker)IBA 05/2022 - 07/2003
33	Clopidogrel (Plavix)FDA Link 01/2020 - 01/2003
26	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2021 - 06/2002
22	vericiguatIBA 11/2022 - 01/2018
21	Prasugrel Hydrochloride FDA Link 01/2020 - 07/2010
19	vorapaxarIBA 12/2018 - 01/2012
19	Glycoproteins (Glycoprotein)IBA 01/2018 - 01/2002
19	Eptifibatide (Integrilin)FDA Link 04/2014 - 01/2002
18	Thrombin Receptors (Thrombin Receptor)IBA 01/2020 - 01/2012
17	CreatinineIBA 01/2020 - 12/2003
16	pro-brain natriuretic peptide (1-76)IBA 01/2020 - 04/2006
16	Enoxaparin (Lovenox)FDA LinkGeneric 07/2013 - 01/2003
15	Tenecteplase FDA Link 01/2020 - 08/2003
14	TroponinIBA 01/2020 - 04/2003
13	Creatine Kinase (Creatine Phosphokinase)IBA 01/2020 - 01/2002
13	MB Form Creatine KinaseIBA 10/2014 - 04/2003
13	Complement System Proteins (Complement)IBA 09/2013 - 09/2003
11	Sitagliptin Phosphate (Januvia)FDA Link 11/2020 - 07/2015
11	Heparin (Liquaemin)FDA LinkGeneric 01/2007 - 01/2003
10	Platelet Membrane GlycoproteinsIBA 10/2007 - 01/2002
8	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 09/2017 - 08/2002
8	Pharmaceutical PreparationsIBA 02/2016 - 01/2002
8	Streptokinase FDA Link 09/2013 - 07/2002
8	Abciximab (ReoPro)FDA Link 07/2010 - 11/2002
7	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2020 - 08/2002
6	paragonIBA 10/2007 - 02/2002
5	Soluble Guanylyl CyclaseIBA 11/2022 - 01/2018
5	DiureticsIBA 11/2022 - 12/2003
5	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 01/2020 - 01/2016
5	darapladibIBA 01/2019 - 05/2014
5	Troponin IIBA 08/2018 - 04/2003
5	EnzymesIBA 05/2014 - 01/2002
5	Warfarin (Coumadin)FDA LinkGeneric 02/2010 - 04/2004
4	Hemoglobins (Hemoglobin)IBA 11/2021 - 02/2005
4	Peptide Hydrolases (Proteases)FDA Link 12/2018 - 03/2014
4	Fibrinolytic Agents (Antithrombotic Agents)IBA 06/2015 - 04/2004
4	Platelet Membrane Glycoprotein IIbIBA 05/2015 - 12/2006
3	Hormones (Hormone)IBA 06/2021 - 09/2010
3	CytokinesIBA 01/2021 - 02/2007
3	Interleukin-6 (Interleukin 6)IBA 01/2021 - 10/2005
3	omega-Chloroacetophenone (Mace)IBA 01/2020 - 08/2016
3	LDL CholesterolIBA 01/2020 - 08/2017
3	Hypoglycemic Agents (Hypoglycemics)IBA 12/2019 - 01/2016
3	HDL CholesterolIBA 01/2019 - 08/2014
3	TicagrelorIBA 01/2018 - 01/2012
3	Angiotensin Receptor AntagonistsIBA 09/2017 - 02/2006
3	C-Reactive ProteinIBA 07/2017 - 10/2005
3	NitrogenIBA 06/2017 - 01/2015
3	Urea (Carbamide)FDA LinkGeneric 06/2017 - 01/2015
3	SodiumIBA 06/2017 - 02/2015
3	PAR-1 ReceptorIBA 12/2015 - 07/2014
3	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 12/2015 - 04/2004

Therapy/Procedure

99	Percutaneous Coronary Intervention 05/2022 - 09/2003
97	Therapeutics 05/2022 - 01/2002
17	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 01/2022 - 01/2002
16	Thrombolytic Therapy 01/2020 - 02/2002
16	Patient Readmission 12/2019 - 02/2009
6	Length of Stay 01/2018 - 02/2004
4	Secondary Prevention 12/2018 - 03/2003
4	Stents 05/2016 - 01/2009
3	Drug-Eluting Stents 09/2014 - 01/2009